Recovering scientist turned early stage VC A biotech optimist fighting gravity

Standing On The Shoulders Of Stem Cell Gene Therapists: History, Hyperbole And Hope For The Future
July 7, 2016

This post was written by Jason Gardner, Atlas EIR and CEO of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC. A new type of medicine was approved in Europe at the end of May that culminated

Leave a comment

Life After The Street: Why Biotech Is Winning Over Wall Street Talent
July 5, 2016

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. About three weeks ago, I attended a dinner organized by a good friend and former sell-side competitor, Dr. Yaron

1 Comment

Biotech BD Transactions: The Soft Stuff
June 27, 2016

This blog was written by Samantha Truex, former CBO of Padlock Therapeutics, as part of the From The Trenches feature of LifeSciVC. I grew up in a setting where “continuous improvement” and “total quality management” were household terms, as unusual

1 Comment

I/O: The Strategic Supernova In Cancer Today
June 22, 2016

With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets,

3 Comments

Life In The Trenches Of A Biotech LLC
June 21, 2016

This blog was written by Jeb Keiper, CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Unsurprisingly, I had not given that much thought to the parent entity of my new employer when I

1 Comment

Digital Health in Clinical Trials
June 9, 2016

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. As a controlled experiment, try placing a tape recorder, rotary phone or record album in front of an 8

Leave a comment

Growth Phase: Avoiding Vertigo During the Ride Up
June 6, 2016

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Startup life can be grueling.  It’s an especially gratifying feeling when your data and your investors signal that it’s

Leave a comment

The White House’s National Microbiome Initiative: My Reflections
June 2, 2016

This blog was written by JC Gutierrez-Ramos, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC.   Despite being central to life on earth, we know little about how microbes interact with each other, their hosts and

1 Comment

Riding The Gene Editing Wave: Reflections On CRISPR/Cas9’s Impressive Trajectory
May 31, 2016

CRISPR/Cas genome editing has captured the attention of the popular media, scientific community, and the investment world: the promise of going into a cell and precisely making changes in their genetic code to cure them of illness is certainly captivating.

5 Comments

Our Experience With First-Time Biotech CEOs: Five Behaviors That Matter
May 25, 2016

Jumping into a first-time CEO role in an emerging biotech is a daunting but exciting opportunity – both for the newly-minted chief executive and their Board of Directors. A great hire can be positively catalytic to a startup; and, sadly,

3 Comments

Of Mice And Men: Translation In Psychiatric Disease
May 12, 2016

This blog was written by Vanessa King, CEO of Luc Therapeutics, as part of the From The Trenches feature of LifeSciVC Almost 15 years ago – in 2003, to be precise – I was working with genome sequencing pioneer Craig

2 Comments

A Tale of Two Startup Worlds: Biotech And Tech VC Ecosystems
May 9, 2016

Startup ecosystems supported by venture capital are defined by dynamism, with the creation, growth, exiting, or failure of new innovative companies conspiring to keep these entrepreneurial landscapes in constant change. Investor returns and sentiment are dramatically impacted by how these

2 Comments